NeuroPace Announces First Patient Implanted In NAUTILUS Pivotal Study For Treatment Of Idiopathic Generalized Epilepsy
Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older
NeuroPace, Inc. (NASDAQ:NPCE), a commercial stage medical device
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
NeuroPace’s Return On Capital Employed Insights
NeuroPace (NASDAQ:NPCE) brought in sales totaling $10.20 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.72%, resulting in a loss of $12.69 million.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $5.5
Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Underweight and lowers the price target from $6 to $5.5.